Tech Company Financing Transactions
Altair Therapeutics Funding Round
On 12/18/2007, Altair Therapeutics raised Series A investment from Forward Ventures, Thomas and McNerny & Partners.
Transaction Overview
Company Name
Announced On
12/18/2007
Transaction Type
Venture Equity
Amount
Unknown
Round
Series A
Investors
Forward Ventures (Joel Martin)
Thomas, McNerny & Partners (Pratik Shah)
Proceeds Purpose
Altair is developing AIR645 (ISIS 369645), an inhaled inhibitor of the IL-4/IL-13 signaling pathways for the treatment of asthma, which continues to be an area of unmet medical need. Altair in-licensed the compound from Isis Pharmaceuticals (NASDAQ:ISIS - News) and the two companies will collaborate to discover drugs directed to other promising targets for the treatment of respiratory conditions.
Company Information
Company Status
Out of Business
Industry
Biopharmaceutical
Mailing Address
12555 High Bluff Dr. 310
San Diego, CA 92130
USA
San Diego, CA 92130
USA
Phone
Website
Email Address
Overview
Altair is building a dedicated team, combining antisense drug discovery expertise with respiratory drug development expertise, to focus solely on the development and commercialization of antisense drugs for the treatment of asthma and other respiratory conditions.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Joel Martin
Chief Financial Officer
Nicole DeBerg
Chief Medical Officer
Michael Hodges
Chief Scientific Officer
Susan Gregory
Browse more venture capital transactions:
Prev: 12/18/2007: Ribbit venture capital transaction
Next: 12/18/2007: Verilogue venture capital transaction
Share this article
Where The Data Comes From
We do our best to record funding rounds that are announced publicly. VC investment data records reported here come from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs